Therapeutic Plasma Exchange Market Size & Share, by End use (Hospitals, Ambulatory Surgical Centers, Research Institutes, Home Care Settings); Application; Type; Technology; Disease Indication; Procedure Type - Global Supply & Demand Analysis, Growth Forecasts, Statistical Report 2026-2035

Therapeutic Plasma Exchange Market - Regional Analysis

North America Market Insights

The North America therapeutic plasma exchange market is anticipated to garner the highest share of 39.4% by the end of 2035. The market’s upliftment in the region is highly driven by an increase in the prevalence of neurological and autoimmune diseases, robust reimbursement policies, and the presence of innovative healthcare facilities. According to official statistics published by the IHME Organization in November 2025, 1 in 2 people in the U.S., which is more than half of the population, is readily impacted by a neurological disease. There are 36 medical conditions, and more than 180 million people, or 54% of the population, comprise at least 1 of these conditions. In addition, tension-type headache is one of the most prevalent conditions affecting 122 million people in the overall region. This is followed by migraine affecting 58 million people and diabetic neuropathy affecting 17 million people, thus bolstering the market’s exposure.

The therapeutic plasma exchange market in the U.S. is growing significantly due to a surge in the incidence of myasthenia gravis and lupus, along with an increase in federal expenditure. Based on government estimates published by the CMS Government in January 2026, the national health expenditure (NHE) increased to 7.2%, amounting to USD 5.3 trillion as of 2024, which is USD 15,474 per person, and further accounted for 18.0% of the country’s gross domestic product (GDP). Likewise, Medicare expenditure surged 7.8% to USD 1,118.0 billion, accounting for 21% of the NHE, while Medicaid expenditure rose 6.6% to USD 931.7 billion, accounting for 18% of the NHE in the same year. Besides, private health insurance spending increased by 8.8% to USD 1,644.6 billion in the same year, accounting for 31% of the NHE, thereby making the therapeutic plasma exchange market suitable for expansion in the country.

National Health Expenditure Analysis in the U.S. (2024)

Source: CMS Government

The aspect of federal healthcare budget, provincial and federal collaboration, universal healthcare partnerships, expansion in donor plasma, an upsurge in provincial reimbursement, and the adoption of innovative apheresis devices are drivers that are uplifting the therapeutic plasma exchange market in Canada. As per an article published by the Commonwealth Fund Organization in 2026, the overall health spending in the country is estimated to have reached 11.5% of the domestic GDP. Additionally, the private and public sectors account for approximately 30% and 70% of the overall health spending, respectively. Besides, provincial and territorial government revenue is considered the ultimate funding source, and based on this, almost 24%, which is an estimated CAD 37 billion (USD 29.4 billion), is significantly offered by the Canada Health Transfer, thus boosting the market’s expansion.

APAC Market Insights

The Asia Pacific therapeutic plasma exchange market is expected to emerge as the fastest-growing region during the forecast period. The market’s development in the region is highly attributed to government-based plasma therapy programs, an expansion in healthcare infrastructure, and the existence of robust government expenditure. Based on government estimates published by the NLM in November 2025, South Asia is considered home to more than 2 billion people, with the facility of achieving universal healthcare coverage. Besides, the health expenditure per capita for Bhutan amounted to USD 154.4, followed by USD 145.5 in Sri Lanka, and USD 61.0 in Bangladesh. Likewise, the governmental health spending amounted to USD 75.6 in Bhutan, USD 58.6 in Sri Lanka, and USD 3.9 in Bangladesh. Besides, the primary healthcare spending in India amounts to USD 28.9 per capita, which is also boosting the market’s exposure in the overall region.

The therapeutic plasma exchange market in China is gaining increased traction due to the aspect of a massive patient population, the provision of government investment in plasma infrastructure, regulatory support, and urban healthcare expansion. As stated in an article published by NLM in December 2025, as of 2023, the country’s population aged more than 60 years effectively reached 280 million, representing over 19% of the total population. Simultaneously, chronic diseases are continuing to increase in prevalence, accounting for over 80% of the domestic disease burden. In addition, the floating population has exceeded 240 million, experiencing acute health risks, while an estimated 85 million citizens with disabilities urgently demand enhanced health services. Therefore, with an increase in health challenges and a rise in diseases, there is a huge growth opportunity for the market in the country.

The presence of public health accessibility programs, an increase in government healthcare expenditure, a high burden of autoimmune diseases, and growth in medical tourism are factors that are propelling the therapeutic plasma exchange market in India. Based on government estimates published by the PIB Government in July 2024, there has been an increase in social welfare expenditure by 12.8% as of 2024, with a surge in health expenditure also increasing by 15.8%. Besides, the spending on social services has also increased to 7.8% of GDP, along with an upsurge in the domestic health spending by 1.9% of GDP in the same year. This growth in social services and healthcare has been underpinned by the effective and transformational implementation of governmental programs, which is creating an optimistic outlook for the market’s growth.

Europe Market Insights

Europe therapeutic plasma exchange market is projected to witness considerable growth by the end of the stipulated timeline. The market’s growth in the region is highly fueled by the presence of robust reimbursement frameworks, regional investment in plasma-based therapies, and a rise in chronic disorders. According to official statistics published by the Europe Commission in March 2025, under the EU4Health, the HaDEA significantly manages 68 projects for supporting the integration of the Europe Health Data Space (EHDS) Regulation, amounting to an overall funding of €105,206,061. This caters to 3 notable projects for preparing the EHDS adoption groundwork, including the Xt-HER for securing the Electronic Health Records (EHR) system, the TEHDAS2 for accessing health data in a secure manner, and the EHDS2 Pilot for sharing health information with the futuristic EHDS.

The therapeutic plasma exchange market in Germany is gaining increased traction due to regional plasma strategies, innovative hospital infrastructure, and an increase in government expenditure. As per a data report published by GTAI in 2022, the pharmaceutical industry's revenue accounted for EUR 46.4 billion, along with 12.5% of revenue in revenue and development. In addition, the yearly revenue growth constituted for 5.1% in the country’s pharmaceutical industry for more than a 5-year duration. Moreover, EUR 83.2 billion has been allocated for exports of pharmaceuticals, which is the world’s largest exporter of medicinal products. Meanwhile, EUR 7.4 billion has been allocated for research and development by pharmaceutical organizations in the country, and 83 million significantly drives the domestic demand for healthcare products and services, which is also bolstering the market’s growth.

The presence of safety legislation, EHDS funding provision, along with innovative apheresis technologies are significantly responsible for uplifting the therapeutic plasma exchange market in the UK. As stated in an article published by the NIHR in May 2023, 19 autoimmune diseases affect almost 10% of the population in the country, constituting 13% of women and 7% of men. Besides, a clinical study was published by NCBI in June 2023, wherein 22,009,375 individuals were evaluated. Based on the evaluation, 978,872 comprised the newest diagnosis of at least 1 autoimmune disease. Additionally, 625,879 diagnosed patients were female, which is 63.9%, and 352,993 were male, which is 36.1%. Besides, during the clinical study, there has been a huge increase in coeliac disease, with an incidence ranging between 2.0 and 2.3, followed by Sjogren’s syndrome, accounting for between 1.8 and 2.3, and Graves’ disease, ranging between 1.9 and 2.2. Therefore, with the increased prevalence, there is a huge growth opportunity for the market in the country.